Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1984 3
1986 1
1988 2
1992 1
1993 4
1994 2
1995 4
1996 4
1997 4
1998 4
1999 13
2000 18
2001 12
2002 20
2003 11
2004 17
2005 14
2006 14
2007 17
2008 15
2009 8
2010 4
2011 9
2012 13
2013 16
2014 12
2015 8
2016 7
2017 5
2018 8
2019 14
2020 8
2021 8
2022 10
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Benign Prostatic Hyperplasia by Natural Drugs.
Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, Kenda M, Kočevar Glavač N, Nagy M, Protti M, Mercolini L, Horváth G, Farkas Á, On Behalf Of The Oemonom. Csikós E, et al. Molecules. 2021 Nov 25;26(23):7141. doi: 10.3390/molecules26237141. Molecules. 2021. PMID: 34885733 Free PMC article. Review.
Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G, Giannarini G, Alcaraz A, Cózar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V. Novara G, et al. Eur Urol Focus. 2016 Dec;2(5):553-561. doi: 10.1016/j.euf.2016.04.002. Epub 2016 Apr 23. Eur Urol Focus. 2016. PMID: 28723522 Review.
Only RCTs reporting on efficacy and safety of Permixon in the treatment of LUTS/BPH were selected. EVIDENCE SYNTHESIS: The systematic search identified 12 RCTs: 7 compared Permixon with placebo; 2 compared Permixon with tamsulosin; 2 compared Permixon …
Only RCTs reporting on efficacy and safety of Permixon in the treatment of LUTS/BPH were selected. EVIDENCE SYNTHESIS: The systematic …
Hexanic Extract of Serenoa repens (Permixon()): A Review in Symptomatic Benign Prostatic Hyperplasia.
Blair HA. Blair HA. Drugs Aging. 2022 Mar;39(3):235-243. doi: 10.1007/s40266-022-00924-3. Epub 2022 Mar 3. Drugs Aging. 2022. PMID: 35237936 Free PMC article. Review.
The hexanic extract (HE) of Serenoa repens (Permixon()) is indicated for the symptomatic treatment of benign prostatic hyperplasia (BPH). ...To avoid side effects often associated with other available treatments such as 5alpha-reductase inhibitors and alpha-blockers, plant …
The hexanic extract (HE) of Serenoa repens (Permixon()) is indicated for the symptomatic treatment of benign prostatic hyperplasia (B …
Permixon, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells.
Tamalunas A, Wendt A, Springer F, Vigodski V, Ciotkowska A, Rutz B, Wang R, Huang R, Liu Y, Schulz H, Ledderose S, Kolben T, Magistro G, Stief CG, Hennenberg M. Tamalunas A, et al. Life Sci. 2022 Nov 1;308:120931. doi: 10.1016/j.lfs.2022.120931. Epub 2022 Sep 6. Life Sci. 2022. PMID: 36084760 Free article.
In contrast, underlying mechanisms were rarely addressed and are only marginally understood. We therefore investigated effects of Permixon on human prostate and detrusor smooth muscle contraction and on growth-related functions in prostate stromal cells. MAIN METHODS: P …
In contrast, underlying mechanisms were rarely addressed and are only marginally understood. We therefore investigated effects of Permixo …
Benign prostate hyperplasia and nutrition.
Das K, Buchholz N. Das K, et al. Clin Nutr ESPEN. 2019 Oct;33:5-11. doi: 10.1016/j.clnesp.2019.07.015. Epub 2019 Aug 12. Clin Nutr ESPEN. 2019. PMID: 31451276
An update on plant derived anti-androgens.
Grant P, Ramasamy S. Grant P, et al. Int J Endocrinol Metab. 2012 Spring;10(2):497-502. doi: 10.5812/ijem.3644. Epub 2012 Apr 20. Int J Endocrinol Metab. 2012. PMID: 23843810 Free PMC article.
Other agents covered include red reishi, which has been shown to reduce levels 5-alpha reductase, the enzyme that facilitates conversion of testosterone to dihydrotestosterone (DHT); licorice, which has phytoestrogen effects and reduces testosterone levels; Chinese peony, which p …
Other agents covered include red reishi, which has been shown to reduce levels 5-alpha reductase, the enzyme that facilitates conversion of …
Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL, Brogden RN. Plosker GL, et al. Drugs Aging. 1996 Nov;9(5):379-95. doi: 10.2165/00002512-199609050-00008. Drugs Aging. 1996. PMID: 8922564 Review.
Serenoa repens (Permixon) has been available for several years for the treatment of men with benign prostatic hyperplasia (BPH). ...
Serenoa repens (Permixon) has been available for several years for the treatment of men with benign prostatic hyperplasia (BPH). ...
Real-world use of Permixon in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
Perry R, Milligan G, Anderson P, Gillon A, White M. Perry R, et al. Adv Ther. 2012 Jun;29(6):538-50. doi: 10.1007/s12325-012-0024-x. Epub 2012 May 25. Adv Ther. 2012. PMID: 22644964
CONCLUSION: In the real clinical world, Permixon is considered an appropriate treatment for BPH as both monotherapy and in combination with alpha-blockers. Prescribing Permixon in combination with alpha-blockers can be demonstrated to provide benefits beyond use of …
CONCLUSION: In the real clinical world, Permixon is considered an appropriate treatment for BPH as both monotherapy and in combinatio …
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW, Donnelly F, Ross M, Habib FK. Bayne CW, et al. Prostate. 1999 Sep 1;40(4):232-41. doi: 10.1002/(sici)1097-0045(19990901)40:4<232::aid-pros4>3.0.co;2-0. Prostate. 1999. PMID: 10420151
Prostate-specific antigen (PSA) secretions into the medium were measured in the presence and absence of Permixon and quantified by an ELISA assay. The morphological patterns before and following Permixon treatment were also examined by electron microscopy. ...The mo …
Prostate-specific antigen (PSA) secretions into the medium were measured in the presence and absence of Permixon and quantified by an …
295 results